Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents

Treatment with hypomethylating agents (HMAs) improves overall survival (OS) in patients who achieve a response of stable disease (SD) or better (complete remission [CR], partial remission [PR], or hematologic improvement [HI]). It is not well established if patients who achieve SD at 4–6 months of t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Res
Main Authors: Nazha, Aziz, Sekeres, Mikkael A., Garcia-Manero, Guillermo, Barnard, John, Al Ali, Najla H., Roboz, Gail J., Steensma, David P., DeZern, Amy E., Zimmerman, Cassie, Jabbour, Elias J., Zell, Katrina, List, Alan F., Kantarjian, Hagop M., Maciejewski, Jaroslaw P., Komrokji, Rami S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4986515/
https://ncbi.nlm.nih.gov/pubmed/26777537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2015.12.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados